Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in August 2024
Insights+: EMA Marketing Authorization of New Drugs in August 2024
Shots:    The EC has approved to 5 Biologics and 3 New Chemical Entities in August 2024, leading to treatments for patients and advances in the healthcare industry   The major highlighted drugs were Johnson & Johnson’s Balversa to treat Metastatic Urothelial Carcinoma (mUC) and Takeda’s Adzynma for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)  PharmaShots has compiled a list…
September 24, 2024
Disease of the Month – Systemic Lupus Erythematosus
Disease of the Month – Systemic Lupus Erythematosus
Shots:  Systemic lupus erythematosus (SLE) is an autoimmune disorder where the body's immune system targets and damages healthy tissues  In this reprise of our Disease of the Month report, we present an enlightening description of SLE with a thorough study of epidemiology, market size, disease management, potential medicines, patient advocacy groups, and the key players involved    For a…
September 18, 2024
Insights+: The US FDA New Drug Approvals in August 2024
Insights+: The US FDA New Drug Approvals in August 2024
Shots:     PharmaShots has compiled a list of US FDA-approved drugs in the month of August 2024     The US FDA has approved a total of 7 new drugs including 4 new molecular entities and 3 biologics leading to the treatments for patients and advances in the healthcare industry       The major highlighted drug was Johnson & Johnson’s Rybrevant plus Lazcluze…
September 10, 2024
Know Your Investor: BVF Partners L.P. (September’24 Edition)
Know Your Investor: BVF Partners L.P. (September’24 Edition)
Shots:  An equity hedge fund manager company, BVF Partners invests in small cap and early-stage biotechnology companies  In 2023, BVF participated in five investment rounds and added 20 companies to its portfolio  For a curated report on a specific investor or venture capital, reach out to us at connect@pharmashots.com  Established in 1993 in San Francisco, California,…
September 5, 2024
Insights+ Key Biosimilars Events of August 2024
Insights+ Key Biosimilars Events of August 2024
Shots:      Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency       Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients       The major highlights were the US FDA’s approval of Sandoz’s Enzeevu for Treating Neovascular Age-Related…
September 3, 2024
Disease of the Month – Gaucher Disease
Disease of the Month – Gaucher Disease
Shots:  Gaucher disease is a rare, autosomal recessive disorder that enlarges organs like the bone marrow, liver, and spleen by depositing fats (lipids) in them  In this reprise of our Disease of the Month report, we present an enlightening description of Gaucher disease with a thorough study of epidemiology, market size, disease management, potential medicines,…
August 28, 2024
New Drug Designations - July 2024
New Drug Designations – July 2024
Shots:   PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA and EMA. This month’s report includes designations allotted to 16 small molecules, 5 biologics, 11 cell & gene therapies, 1 recombinant protein, 1 vaccine, 1 immunotherapy, 1 radiopharmaceutical, 1 antisense oligonucleotide, 3 RNA therapies 1 herbal medicine…
August 27, 2024
Know Your Investor: Arch Venture Partners (August’24 Edition)
Know Your Investor: Arch Venture Partners (August’24 Edition)
Shots: In the August Edition of the Know Your Investor series, we bring a condensed yet illuminating report on Arch Venture Partners  In 2023, Arch Ventures Partners participated in 6 investment rounds and added 27 companies focusing on biopharma and manufacturing & services to its portfolio For a detailed report on all the investments, reach…
August 21, 2024
Insights + EMA Marketing Authorization of New Drugs in July 2024
Insights+: EMA Marketing Authorization of New Drugs in July 2024
Shots:    The EMA granted Positive Opinion to 2 Biologics and 5 New Chemical Entities in July 2024, leading to treatments for patients and advances in the healthcare industry   The major highlighted drugs were Johnson & Johnson’s Yuvanci to treat Pulmonary Arterial Hypertension (PAH) and Astellas’ Vyloy + CT for Gastric & Gastroesophageal Junction Cancer   PharmaShots has compiled a list…
August 14, 2024
Insights+ The US FDA New Drug Approvals in July 2024
Insights+: The US FDA New Drug Approvals in July 2024
Shots:     PharmaShots has compiled a list of US FDA-approved drugs in the month of July 2024     The US FDA approved a total of 2 new drugs including 1 new molecular entity and 1 biologic leading to the treatments for patients and advances in the healthcare industry       The major highlighted drug was Eli Lilly’s Kisunla for…
August 13, 2024
Load more